Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Contact
103 Carnegie Center Drive
Suite 300
PrincetonNJ08852
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.10 | 40.60 | -0.44% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,753.02 | 884.98 | -3.59% |
| Dow JONES (US) | 48,561.44 | 343.34 | -0.70% |
| FTSE 100 | 10,452.50 | 327.61 | -3.04% |
| HKSE | 24,970.38 | 797.70 | -3.10% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 54,031.61 | 2,247.44 | -3.99% |
| NZX 50 Index | 13,531.12 | 125.53 | -0.92% |
| S&P 500 | 6,827.79 | 53.83 | -0.78% |
| S&P/ASX 200 | 8,901.20 | 35.80 | -0.40% |
| SSE Composite Index | 4,068.81 | 53.86 | -1.31% |